Focus on cardiometabolic risk factors

Figures & data

Figure 1. Stepwise CVD risk stratification pathway using plaque grading by 2D/3D ultrasound (from reference 13].

Figure 2. Comparison of the two Lp(a) measurements. The black lines correspond to the limit of 180 mg/dL, differentiating between false negatives and false positives (from reference 16].

Figure 3. Risk-based LDL-C goal attainment in primary and secondary prevention patients (from reference 17].

Sprynger M, Lancellotti P. Comments on association of HbA1c with carotid artery plaques in patients with coronary heart disease. Acta Cardiol. 2023;78(5):635–636.

 PubMed Web of Science ®Google Scholar

Deconinck A, Morra S, Glassée N, et al. Value of repeated measurements of lipoprotein (a) to assess cardiovascular risk: a retrospective study. Acta Cardiol. 2023;78(5):536–542. doi: 10.1080/00015385.2022.2031377.

 PubMed Web of Science ®Google Scholar

van de Borne P, Peeters A, Leone A, et al. Lipid-lowering therapy and risk-based LDL-C goal attainment in Belgium: DA VINCI observational study. Acta Cardiol. 2022;20:1–10. doi: 10.1080/00015385.2022.2030568.

 Web of Science ®Google Scholar